CIK 0001842295 · Non-accelerated filer<br>Emerging growth company
Maze Therapeutics, Inc.
Sign in to watch- Ticker
- MAZE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 6508505070
- Business address
- 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,785,701
- in 13 filings, $4.6M under 10b5-1 plans
Net −$5,785,701. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-12-30 | Bachrodt Amy SVP, Finance | Sale 10b5-1 | −5,000 | $40.08 | $200K | 12,965 |
| 2025-12-30 | Bachrodt Amy SVP, Finance | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,395 | 1 | ||
| 2025-12-30 | Bachrodt Amy SVP, Finance | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,605 | 2,581 | ||
| 2025-12-30 | Dandekar Atul CSBO | Option exercise 10b5-1 | +100 | $10.42 | $1K | 10,603 |
| 2025-12-30 | Dandekar Atul CSBO | Sale 10b5-1 | −100 | $40.36 | $4K | 10,503 |
| 2025-12-30 | Dandekar Atul CSBO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −100 | 74,143 | ||
| 2025-12-29 | Bachrodt Amy SVP, Finance | Option exercise 10b5-1 | +124 | $10.42 | $1K | 13,089 |
| 2025-12-29 | Bachrodt Amy SVP, Finance | Option exercise 10b5-1 | +9,876 | $10.42 | $103K | 22,965 |
| 2025-12-29 | Bachrodt Amy SVP, Finance | Sale 10b5-1 | −9,400 | $40.54 | $381K | 13,565 |
| 2025-12-29 | Bachrodt Amy SVP, Finance | Sale 10b5-1 | −600 | $41.16 | $25K | 12,965 |
| 2025-12-29 | Bachrodt Amy SVP, Finance | Option exercise · Stock Option (Right to Buy) 10b5-1 | −124 | 2,396 | ||
| 2025-12-29 | Bachrodt Amy SVP, Finance | Option exercise · Stock Option (Right to Buy) 10b5-1 | −9,876 | 23,834 | ||
| 2025-12-29 | Bernstein Harold President, R&D & CMO | Option exercise 10b5-1 | +45,000 | $10.42 | $469K | 45,000 |
| 2025-12-29 | Bernstein Harold President, R&D & CMO | Sale 10b5-1 | −27,800 | $40.34 | $1.1M | 17,200 |
| 2025-12-29 | Bernstein Harold President, R&D & CMO | Sale 10b5-1 | −17,200 | $40.93 | $704K | 0 |
| 2025-12-29 | Bernstein Harold President, R&D & CMO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −45,000 | 342,407 | ||
| 2025-12-29 | Dandekar Atul CSBO | Option exercise 10b5-1 | +72,400 | $10.42 | $754K | 82,903 |
| 2025-12-29 | Dandekar Atul CSBO | Sale 10b5-1 | −66,365 | $40.51 | $2.7M | 16,538 |
| 2025-12-29 | Dandekar Atul CSBO | Sale 10b5-1 | −6,035 | $41.13 | $248K | 10,503 |
| 2025-12-29 | Dandekar Atul CSBO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −72,400 | 74,243 |
Page 11 of 14 · 267 trades